Aspreva Pharmaceuticals, Inc. (ASPV: chart) priced its IPO of 7.2 million shares below the expected range at $11 per share, raising $79.2 million. The company had filed for an offering in the price range of $13 to $15 per share.

Aspreva is a pharmaceutical company focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations.

The underwriters, led by Merrill Lynch & Co., have the option to purchase an additional 1.08 million shares to cover over-allotments.

Shares of Canada-based Aspreva closed Friday at $14.79, up $3.79, or 34.5%.

First in the IPO lineup to price this week is expected to be the Boston-based biopharmaceutical company CombinatoRx, Inc. (CRXX: chart), which set the terms of the company's pending IPO at 6 million shares. The company will be shooting at a price range between $10 and $12, to raise $72 million.

CombinatoRx is a biopharmaceutical company focused on developing oncology, and immuno-inflammatory drugs.

Leading the deal's underwriting syndicate is Merrill Lynch & Co., with co-leader Banc of America Securities LLC.

International Securities Exchange (ISE: chart), the largest equity options exchange in the world, raised its expected price range to $16 to $18 from $14 to $16. About 10 million shares are being offered on this IPO to raise about $173.4 million.

Bear Stearns & Co. and Morgan Stanley are the lead underwriters for the offering.

The Israeli-based progressive lens-maker Shamir Optical Industry Ltd. (SHMR: chart) is expected to price 4 million common shares for between $13 and $15 per share. The company plans to sell 3.4 million shares and shareholders plan to sell another 600,000 shares.

William Blair & Company, CIBC World Markets C.E. Unterberg, Towbin are the underwriters managing the offering.